Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone

Pinnamaneni, K.; Yap, H.Y.; Buzdar, A.U.; Distefano, A.; Blumenschein, G.R.

Cancer 53(9): 1841-1844

1984


ISSN/ISBN: 0008-543X
PMID: 6546706
DOI: 10.1002/1097-0142(19840501)53:9<1841::aid-cncr2820530907>3.0.co;2-#
Accession: 004681422

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Evaluable patients (26) with metastatic breast carcinoma previously treated with a combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) were treated with a combination of doxorubicin (Adriamycin), dibromodulcitol and mitomycin (ADM). Four patients (15%) achieved complete remission, and 10 patients (39%) had a partial response. Five patients (19%) had stable disease and 7 patients (27%) experienced disease progression. The median time to disease progression was 10 mo. for responding patients (range, 4-44 mo.) and 5 mo. (range, 2-13 mo.) for patients with stable disease. The median survival duration was 15 mo. (range, 6-44+ mo.) for responders, 11 mo. (range, 2-27 mo.) for patients with stable disease and 4 mo. (range, 2-41 mo.) for nonresponders. Of the 4 patients with complete remission 2 are alive and in continued remission at a follow-up of 44 and 40 mo. Patients (71) with .gtoreq. 2 sites of metastasis responded, whereas 23% of patients with .gtoreq. 3 metastatic sites responded. Although higher responses were seen with soft tissue and osseous metastasis, responses were observed in all 3 sites of metastasis. This combination chemotherapy regimen with ADM is an effective 2nd-line program for patients who have previously received CMFVP chemotherapy.